Company Insights

LAB customer relationships

Explore interactive graphBrowse insights index
LAB customer relationship map

Standard BioTools (LAB): Customer Relationships and Strategic Implications for Investors

Standard BioTools operates as a diversified life-sciences tools company that monetizes through equipment sales, consumables, lab services, software, licensing and royalties. The company generates product revenue from instruments and reagents, service revenue from lab and field services (including the SomaScan® assay), and non-product revenue from licenses and royalties; strategic asset sales, notably the divestiture of SomaLogic to Illumina, have materially altered its cash position and strategic focus. For investors and operators evaluating customer exposure, the company’s model combines recurring service contracts with capital-equipment cycles and licensing revenue, creating a mixed margin and cadence profile that rewards scale in both installed base and lab services throughput.
Learn more about our analysis framework at https://nullexposure.com/.

A decisive divestiture and what it means for customer exposure

Standard BioTools completed the sale of SomaLogic to Illumina in January 2026 for $350 million upfront and up to $75 million in near-term earnouts (up to $425 million total), plus specified royalties, a transaction announced publicly in late January 2026. That deal converts an operating asset into near-term cash and future royalty streams, materially strengthening the balance sheet and reducing direct exposure to the SomaLogic customer base while preserving upside through royalties. According to company disclosures and multiple press releases in early 2026, the transaction closed in January and is reflected in FY2026 reporting as a completed divestiture.

Strategic takeaways from the sale

  • Immediate liquidity and balance-sheet repair: The sale supplies cash and de-risks ongoing operating funding needs. (GlobeNewswire; Jan–Feb 2026.)
  • Shift from direct-service to royalty-led exposure: Future revenue from the sold unit will rely on contractual royalties rather than direct lab-service volume under LAB’s control. (GlobeNewswire; Jan 30, 2026.)

If you want a concise vendor-customer risk map built from these relationships, visit https://nullexposure.com/ for actionable investor tools.

Company-level operating constraints and how they shape customer risk

Standard BioTools’ operational profile generates several clear constraints that affect customer relationships and revenue durability:

  • Contracting posture — hybrid of licensing and multi-year service contracts. The company recognizes license and royalty revenue when a license transfers to the customer, and field services revenue is generally recognized straight-line over one- to four-year terms, indicating a mix of near-term and multi-year revenue streams. This points to predictable recurring revenue from service contracts and lumpy, event-driven licensing inflows.

  • Customer composition — academic, government and non-profit exposure. The company explicitly sells to leading academic, government, pharmaceutical, biotech, and clinical labs worldwide, which creates revenue durability but also concentration around grant cycles and public-sector procurement timing.

  • Geographic diversification — true global footprint. With roughly half of revenue historically from outside the U.S. (48% in 2024), the business is geographically diversified, which reduces single-country demand risk but increases exposure to cross-border logistics and currency.

  • Role mix — seller, distributor, and service provider. LAB operates as a manufacturer/seller of hardware and consumables, uses distributors in some territories, and generates lab services revenue from performing assays — a multi-role posture that balances margin and reach but adds operational complexity.

  • Portfolio mix — hardware, services, software. The company’s product set spans instruments and consumables (hardware), lab and field services, and software — a mix that blends capital equipment cycles with recurring consumables and service revenue, supporting higher lifetime customer value but requiring ongoing R&D and field support maturity.

These constraints together indicate a company with moderate contractual stickiness, diversified but complex customer relationships, and a hybrid revenue profile that benefits from installed-base scale.

Who matters to LAB today — customer relationships you need to know

Illumina, Inc. (ILMN)

Standard BioTools completed the sale of SomaLogic to Illumina in January 2026 for $350 million in upfront cash and up to $75 million in near-term earnouts (aggregate up to $425 million), plus specified royalties; the transaction closed in January and is reflected in FY2026 reporting. (GlobeNewswire press releases, Jan–Feb 2026; InvestingNews FY2025 commentary.) The company’s 2025 Q1 commentary also notes re-engagement with Illumina as a “key partner,” signaling an ongoing commercial or technical relationship even after the divestiture. (LAB 2025 Q1 earnings call.)

AstraZeneca (AZN)

SomaScan data and analyses that originated from Standard BioTools’ platform were cited in studies with AstraZeneca relating to the prediction and monitoring of serious lung complications from cancer treatment, indicating pharma-level validation of the platform’s clinical research utility. (LAB 2025 Q1 earnings call.)

Daiichi Sankyo (DSKYF)

Similarly, research collaborations involving Daiichi Sankyo and AstraZeneca used SomaScan data across Phase II and Phase III clinical programs to evaluate predictive biomarkers for treatment complications, reflecting engagement with major pharmaceutical development programs. (LAB 2025 Q1 earnings call.)

What investors and operators should watch next

  • Royalty realization vs. service revenue replacement: With SomaLogic sold for cash plus royalties, monitor how quickly licensing and consumables revenue can be replaced or complemented by other services and product lines; royalty timing will be uneven and contractually defined. (GlobeNewswire; Feb 2026.)

  • Contract maturity and renewal cadence: One- to four-year service contracts create a near-term visibility window; watch renewal rates and any migration of customers to third-party or newly combined solutions following the Illumina closing. (Company revenue recognition disclosures.)

  • Customer concentration and public-sector timing: Heavy exposure to academic and government buyers implies procurement seasonality and potential sensitivity to public funding cycles; diversification into commercial pharma partnerships and recurring consumables will be essential.

  • Operational execution on hardware and software integration: The mixed portfolio demands competent field service and software support to maximize installed-base consumables sales and lab throughput.

If you need a tailored exposure brief that maps LAB’s customers to cash-flow impact and contractual timing, explore our resources at https://nullexposure.com/.

Bottom line

Standard BioTools has transformed a portion of its risk profile through the SomaLogic divestiture, converting operating exposure into cash and royalties while retaining service and product businesses that drive recurring revenue. Investors should weigh the improved balance sheet against the need to replace direct service volumes with new product adoption and royalty realization, while tracking multi-year service contract renewals and global demand patterns. For operators, the imperative is clear: preserve installed-base uptime, convert pharma collaborations into repeatable commercial engagements, and leverage software and consumables to stabilize margins.